Previous 10 | Next 10 |
2023-05-16 06:51:24 ET NRx Pharmaceuticals press release ( NASDAQ: NRXP ): Q1 GAAP EPS of -$0.16. Ended quarter with $16.5 million in cash and cash equivalents For further details see: NRx Pharmaceuticals GAAP EPS of -$0.16
NRx Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update PR Newswire Enrollment continues in the Phase 2b /3 clinical trial evaluating NRX-101 in Suicidal Treatment-Resistant Bipolar Depression; data expected in 4Q 2023 National edu...
NRx Pharmaceuticals Reschedules First Quarter 2023 Financial Results Conference Call PR Newswire RADNOR, Pa. , May 10, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical co...
NRx Pharmaceuticals to Report First Quarter 2023 Financial Results on May 11, 2023 PR Newswire RADNOR, Pa. , April 27, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company...
2023-03-30 22:10:12 ET NRx Pharmaceuticals, Inc. (NRXP) Q4 2022 Earnings Conference Call March 30, 2023 04:30 PM ET Company Participants Suzanne Messere - IR Stephen Willard - CEO Seth Van Voorhees - CFO Jonathan Javitt - Chief Scientist Conference Call...
2023-03-30 16:13:48 ET NRx Pharmaceuticals press release ( NASDAQ: NRXP ): FY GAAP EPS of -$0.61. As of December 31, 2022, the cash balance was $20.1 million compared to $27.6 million as of December 31, 2021. For further details see: NRx Pharmaceuticals GAAP EPS ...
NRx Pharmaceuticals Reports Full Year 2022 Financial Results and Provides Business Update PR Newswire Over the past 12 months, the Company reinitiated its psychiatry development program post pandemic, transferred manufacturing of NRX-101 to the US, and initiated a clinical tri...
2023-03-29 17:35:59 ET Major earnings expected after the bell on Thursday include: BlackeBerry Limited ( BB ) Skillz ( SKLZ ) Canoo ( GOEV ) IonQ ( IONQ ) Astra Space ( ASTR ) For further details see: Notable earnings after Thursday's close
2023-03-27 12:07:57 ET NRx Pharmaceuticals ( NASDAQ: NRXP ) said Monday the independent Data Safety Monitoring Board has recommended the continuation of a planned patient enrollment for a trial evaluating NRX-101. NRX-101 is the company's proposed treatment for sever...
NRx Pharmaceuticals Announces Positive Recommendation to Continue Enrollment in the Ongoing Trial of NRX-101 in Patients with Suicidal Treatment-Resistant Bipolar Depression PR Newswire · The independent Data Safety Monitoring Board recommended continuation of patient...
News, Short Squeeze, Breakout and More Instantly...
NRX Pharmaceuticals Inc. Company Name:
NRXP Stock Symbol:
NASDAQ Market:
NRX Pharmaceuticals Inc. Website:
NRx Pharmaceuticals (NASDAQ:NRXP) to Proceed with Two New Drug Applications in 2024; NRX-101 has Been Returned to the Company for Filing PR Newswire New Drug Application (NDA) for Accelerated Approval planned for NRX-101 in people with bipolar depression and akathisia in 202...
NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference on June 27, 2024 PR Newswire RADNOR, Pa. , June 20, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals"...
NRx Pharmaceuticals (NASDAQ:NRXP) Appoints Neuroscience, Information Technology and Medical Technology Veteran to its Board of Directors PR Newswire Dr. Dennis McBride brings extensive experience in Neuroscience and its interface with Information and Medical Technology ...